Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery

Breast

Volumn 19, Issue 5, 2010, Pages 339-344

  Murray, L J ^a   Ramakrishnan, S ^a   O'Toole, L ^b   Manifold, I H ^a   Purohit, O P ^a   Coleman, R E ^c  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adjuvant trastuzumab; Left ventricular ejection fraction

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM EXAMINATION; CLINICAL PRACTICE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEALTH CARE DELIVERY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; THERAPY DELAY;

EID: 77957117224     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.02.001     Document Type: Article

References (29)

1. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353(16):1659-1672.
2. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., et al. 2 year follow-up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer: a randomised control trial. Lancet 2007, 369:29-36.
3. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for adjuvant HER-2 positive breast cancer. N Eng J Med 2005, 353(16):1673-1684.
4. Perez E.A., Romond E.H., Suman V.J., Jeong J., Davidson N.E., Geyer C.E., et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Proc Am Soc Clin Oncol 2007, [abstract 512].
5. Slamon D., Eiermann W., Robert N. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and Trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005, 94:S5a.
6. Suter T.M., Procter M., van Veldhuisen D.J., van Muscholl M., Bergh J., Carlomango C., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007, 25(25):3859-3865.
7. Tan-Chiu E., Yothers G., Romond E., Geyer C.E., Ewer M., Keefe D., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23(31):7811-7819.
8. Rastogi P., Jeong J., Geyer C.E., Costantino J.P., Romond E.H., Ewer M.S., et al. Five year update of cardiac dysfunction on NSABP B-31, a randomised trial of sequential doxorubicin/cyclophosphamide (AC)- paclitaxel (T) vs AC-T with trastuzumab (H) [abstract 513]. Proc Am Soc Oncol 2007, 25:513.
9. Perez E.A., Suman V.J., Davidson N.E., Sledge G.W., Kaufman P.A., Hudis C.A., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatmant Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26:1231-1238.
10. National Cancer Research Institute Breast Clinical Studies Group. UK Guidelines for the use of adjuvant trastuzumab (herceptin) with or following chemotherapy in HER2-positive early breast cancer. Dec 2005.
11. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standards committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echo Cardiogr 2005, 18:1440-1463.
12. Mahadevan G., Davis R.C., Frenneaux M.P., Hobbs F.D.R., Lip G.Y.H., Sanderson J.E., et al. Left ventricular ejection fraction: are the revised cut-off points for defining systolic dysfunction sufficiently evidence based?. Heart 2008, 94(4):426-428.
13. Jones A.L., Barlow M., Barrett-Lee P.J., Canney P.A., Gilmour I.M., Robb S.D., et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute (NCRI) recommendations for monitoring. Br J Cancer 2009, 100:684-692.
14. Pfisterer M.E., Battler A., Zaret B.L. Range of normal values for left and right ventricular ejection fraction at rest and during exercise assessed by radionuclide angiocardiography. Eur Heart J 1985, 6(8):647-655.
15. Ababneh A.A., Sciacca R.R., Kim B., Bergmann S.R. Normal limits for left ventricular ejection fraction and volumes estimated with gated myocardial perfusion imaging in patients with normal exercise test results: influence of tracer, gender, and acquisition camera. J Nucl Cardiol 2000, 7(6):661-668.
16. Van Royen N., Jaffe C.C., Krumholz H.M., Johnson K.M., Lynch P.J., Natale D., et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 1996, 77:843-850.
17. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993, 342:821-828.
18. Arnold J.M., Yusuf S., Young J., Mathew J., Johnstone D., Avezum A., et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluaiton (HOPE) Study. Circulation 2003, 107:1284-1290.
19. CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987, 316:1429-1435.
20. Moye L.A., Pfeffer M.A., Wun C.C., Davis B.R., Geltman E., Hayes D., et al. Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular enlargement study. Eur Heart J 1994, 15(Suppl B):2-8. [discussion 26-30].
21. SOLVD Investigators Effect of ramipril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Eng J Med 1992, 327:685-691.
22. SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Eng J Med 1991, 325:293-302.
23. Cardinale D., Colombo A., Sandri M.T., Lamantia G., Colombo N., Civelli M., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114:2472-2481.
24. Heart Health and Cancer New data suggests chemotherapy patients benefit from heart failure treatment. MD Anderson News Release 2002, [accessed 17.01.09]. http://www.mdanderson.org/topics/heart-health/display.cfm/id%3D3c7f9f1f-86e6-4eec-ae55548743f3f418&;method%3Ddisplayfull&pn%3D3df9619e-a065-4ec1-b56966d4539e4d94.
25. Ewer M.S., Lippman S.M. Type II chemotherapy-related cardiac dyunction: time to recognise a new entity. J Clin Oncol 2005, 23:2900-2902.
26. Ewer M.S., Vooletich M.T., Durand J.-B., Woods M.L., Davis J.R., Valero V., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
27. Ewer M.S., Lenihan D.J. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Oncol 2008, 26(8):1201-1203.
28. Schneider J.W., Chang A.Y., Garratt A. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol 2002, 29:22-28.
29. Lenihan D., Tong A., Divakarin V., Yusuf S.W., Fadol A., Pai S., et al. Trastuzumab(T) (Herceptin)- associated cardiomyopathy: sequential stress and response to ACE-inhibitors and carvedilol therapy. J Cardiac Fail 2003, 9(5). Suppl 102 abstract 383.